MCO-010 therapy delivers lasting vision improvement in four-year trial
Nanoscope Therapeutics announced that Christine Kay, MD, will present four-year follow-up data from the RESTORE Phase 2b/3 trial of MCO-010 (sonpiretigene isteparvovec, MOGENRY) for retinitis pigmentosa at the 59th Annual Scientific Meeting of the Retina Society in Los Angeles on 23 September 2026,
<p>Nanoscope Therapeutics announced that Christine Kay, MD, will present four-year follow-up data from the RESTORE Phase 2b/3 trial of MCO-010 (sonpiretigene isteparvovec, MOGENRY) for retinitis pigmentosa at the 59th Annual Scientific Meeting of the Retina Society in Los Angeles on 23 September 2026, </p>